Revised Outcome Of Board Meeting Dated 03Rd October, 2026.
Filed with BSE · ISIN INE194R01017 · · 4 pages · English
Summary by 6ix AI
This filing is a notification regarding the revised outcome of a board meeting held by Fredun Pharmaceuticals Ltd. on a specific date. The company has allotted a significant number of equity shares to non-promoter allottees following the conversion of warrants as part of a bonus issue. The details of the allotment, including the names of the allottees and the number of shares issued, are provided in the document. The filing also includes compliance information as required by regulatory authorities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Fredun Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Fredun Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Allotment
- Board Meeting Outcome for Allotment Of 1,82,400 Equity Shares To Non-Promoter Allottees Pursuant To Conversion Of 60,800 Warrants Into Equity Shares, Consequent To The 1: 2 Bonus Issue.
- Fredun Pharmaceuticals Ltd. Press Release Sep 22 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 15 2026
- Fredun Pharmaceuticals Ltd. Press Release Sep 08 2026
Later from Fredun Pharmaceuticals
- Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Follow Fredun Pharmaceuticals into a list and get an email when it puts out news.
Follow Fredun Pharmaceuticals